{"entity":{"id":"gamgee","kind":"company","name":"Gamgee","aka":[],"tldr":"Gamgee sequences a dog's tumour and designs a personalised mRNA vaccine that teaches its immune system what to attack, and is running trials in Australia with the aim of improving the approach with every case.","summary":"Gamgee began when its founder used AI and genomic analysis to design what is believed to be the first fully computationally designed mRNA cancer vaccine given to a dog, with scientists at UNSW; several tumours shrank. The company now runs an end-to-end platform for personalised neoantigen mRNA vaccines in dogs, from veterinary intake and tissue collection through sequencing, vaccine manufacture, treatment and response monitoring, with clinical trials in Australia. It is a veterinary business included for its comparative oncology value; human applications are not claimed.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gamgee"},{"label":"Official website","url":"https://gamgee.io"}],"tags":["veterinary","comparative-oncology"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://gamgee.io","stage":"startup","ycBatch":"S26","investors":["y-combinator"],"funding":[]},"route":"/companies/gamgee/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}